Results 41 to 50 of about 11,145 (294)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source

Morphologic, dynamic and high-resolution microscopy MRI in early-onset spondyloarthritis finger dactylitis

Skeletal Radiology, 2022
Objective Up to now, the pathophysiology of SpA dactylitis has not been entirely clarified. It is not clear which are the involved tissues and which is the primary lesion of the “sausage-like” digit.
E. Scarano, M. Gilio, G. Belmonte, F. Borraccia, A. Padula, G. Guglielmi, S. d'Angelo   +6 more
semanticscholar   +1 more source

Ultrasound Imaging in Psoriatic Arthritis: What Have We Learnt in the Last Five Years?

Frontiers in Medicine, 2020
Psoriatic arthritis (PsA) is a complex heterogeneous disease with multiple inter-related pathologies such as synovitis, enthesitis, tendinopathy, and dactylitis.
Sayam R. Dubash, Sayam R. Dubash, Gabriele De Marco, Gabriele De Marco, Richard J. Wakefield, Richard J. Wakefield, Ai Lyn Tan, Ai Lyn Tan, Dennis McGonagle, Dennis McGonagle, Helena Marzo-Ortega, Helena Marzo-Ortega   +11 more
doaj   +1 more source

Pure peripheral spondyloarthritis, is it exceedingly rare? A real-world experience from an Indian tertiary care hospital

Journal of Marine Medical Society, 2022
Background: Peripheral spondyloarthritis (pSpA) is usually associated with psoriasis, inflammatory bowel disease, or preceding infection (called reactive arthritis).
Arun Hegde, Vishal Mangal, Vivek Vasdev, Kavita Singh, Kovilapu Uday Bhanu   +4 more
doaj   +1 more source

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis [PDF]

, 2015
Objective. To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). Methods. ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment.
Karunaratne, P Mahinda, Mease, Philip, Pangan, Aileen L, Rahman, Proton, Sieper, Joachim, Van den Bosch, Filip   +5 more
core   +1 more source

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial [PDF]

, 2014
Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. Methods: In
Alten, R., Birbara, C., Boh, E., Braun, J., Budd, J., Chattapadhyay, C., Chudzik, D., Claudepierre, P., Cooper, R., Dooley, L. T., Doyle, M. K., Drescher, E., Dutz, J., Edwards, C., El-Kadi, H., Elewski, B., Erlacher, L., Flipo, R., Fretzin, S., George, E., Gladstein, G., Gottlieb, A. B., Griffin, R., Grisanti, M., Guenther, L., Gulliver, W., Hobbs, K., Huang, E., Ilivanova, E., Jeka, S., Kavanaugh, A., Khraishi, M., Kokhan, M., Korman, N., Kunynetz, R., Leonardi, C., Lessard, C., Li, S., Lindquist, U., Martin, A., Matheson, R., McInnes, I.B., Mendelsohn, A. M., Murphy, F., Nasonov, E., Palmer, W., Papp, K., Perate, M., Puig, L., Rahman, P., Rech, J., Rell-Bakalarska, M., Rich, P., Ritchlin, C., Rosen, C., Rudin, A., Ruppert-Roth, A., Scheinecker, C., Seigel, S., Shaikh, S., Sheeran, T., Shen, Y.-K., Shergy, W., Siegel, E., Sierakowski, S., Sofen, H., Szanto, S., Tahir, H., Telegdy, E., Toth, D., Walker, D., Wang, Y., Whitman, M., Wilson, A., Witt, M., Wollenhaupt, J., Zoschke, D., Zubrzycka, A.   +77 more
core   +1 more source

Secukinumab: a new treatment option for psoriatic arthritis [PDF]

, 2016
Introduction: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life.
McInnes, Iain B., Mease, Philip
core   +1 more source

Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study

Rheumatology and Therapy, 2022
To stratify psoriatic arthritis (PsA) patients based on psoriasis (PsO) onset age: early onset psoriasis (EOP) vs. late onset psoriasis (LOP), and to assess if there are differences in disease characteristics, activity/function/impact of the disease, and
S. Scriffignano, F. Perrotta, Mario di Marino, F. Ciccia, E. Lubrano   +4 more
semanticscholar   +1 more source

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study [PDF]

, 2017
Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2,
Delicha, Eumorphia-Maria, Gottlieb, Alice B., Kajekar, Radhika, Kirkham, Bruce, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T.   +9 more
core   +2 more sources

Tuberculous Dactylitis in a Case of Multiple Scrofuloderma

Case Reports in Dermatology, 2022
This paper reports a case of tuberculous dactylitis and multiple scrofuloderma spreading through the lymph nodes. Scrofuloderma, also known as tuberculosis colliquativa cutis, is a form of cutaneous tuberculosis (TB) that occurs most often in children ...
S. Menaldi, Farah Faulin Lubis, Jhauharina Rizki Fadhilla, Sandra Widaty   +3 more
semanticscholar   +1 more source